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To model islet amyloidogenesis in NIDDM and explore the glucoregulatory role of islet amylotd polypeptide (IAPP). we have created transgemc 
mice containing a rat insulin-1 promoter--human IAPP fusion gene. Expression of human IAPP was localized to the islets of Langerhans. anterior 
pituitary and bram in transgemc ammals; blood IAPP levels were elevated 5-fold while fasting glucose levels remained normal. Amyloid deposits 
have not been detected m transgenic islets suggestmg that other co-existing abnormahtites m NIDDM may be required for the formation of islet 
amyloid. These animals provide a unique model for explormg this hypothesis and other proposed functions of IAPP. 
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1. INTRODUCTION 
NIDDM or Type II diabetes mellitus, is character- 
ized by peripheral insulin resistance, hyperglycemia, im- 
paired insulin secretion and the development of amyloid 
deposits in the islets of Langerhans. The principle com- 
ponent of islet amyloid is a 37 amino acid peptide 
termed, islet amyloid polypeptide (IAPP), also known 
as diabetes-associated peptide or amylin. which shares 
45% sequence identity with calcitonin gene-related pep- 
tide [ll4]. IAPP is synthesized as a larger precursor 
protein in the islet beta cells and is processed, stored and 
coreleased with insulin into the blood stream [5-81. 
A major unresolved question concerns the causal re- 
lationship between islet amyloid formation and beta cell 
dysfunction in NIDDM [9-l I]. Pancreatic amyloid is 
found in > 90% of NIDDM patients and to a lesser 
extent in the nondiabetic elderly. IAPP amyloid has also 
been found in nonhuman primates, cats and raccoons 
in association with diabetes but not in species such as 
rats, mice and dogs [9,10]. Recent in vitro studies have 
linked this species-specificity to interspecies differences 
in residues 20-29 of the IAPP sequence thus providing 
important clues to the structural requirements for amy- 
loidogenesis [ 12,131. Understanding the in vivo biologi- 
cal changes which result in IAPP amyloidogenesis, how- 
ever, has proven more difficult. 
concerns the biologic function(s) of this peptide. Struc- 
turally IAPP has the features of an endocrine hormone 
and has been proposed to have glucoregulatory activi- 
ties. IAPP has been reported to inhibit insulin secretion 
from the pancreatic islets in some studies [14-161 but 
not others [17-191. IAPP has also been shown to inhibit 
insulin-stimulated glycogen synthesis in muscle strips in 
vitro, and to antagonize insulin action. induce impaired 
glucose tolerance and elevate plasma glucose levels in 
vivo [20]. However, these responses have primarily been 
observed using pharmacologic doses of IAPP; studies 
using physiologic amounts of IAPP in vivo have not 
confirmed these findings [31-231. Other less well-char- 
acterized biologic activities of IAPP that have been re- 
ported include effects on calcium homeostasis [24], am- 
nesia [25] and anorexia [26,27]. 
In light of the many unresolved questions concerning 
the biologic function(s) of IAPP and its potential role 
in NIDDM, we have created, and describe herein. a 
transgenic animal model in which the consequences of 
overexpressing human (amyloidogenic) IAPP in the is- 
lets of Langerhans and blood can be directly addressed. 
2. MATERIALS AND METHODS 
A second and controversial area of interest in IAPP 
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The transgene used was created by fusmg a 523 bp BuviHI-HlndI11 
DNA restriction fragment encompassing the rat msuhn-I gene pro- 
moter region upstream of a 7.7 kb genomic DNA fragment containing 
the complete human IAPP gene. A Bs.vHI restriction fragment con- 
tainmg the transgene Insert (designated. RI 1 P-glAPP) was gel-purified 
and microinjected into FVBlN mouse (Tacomc. Germantoan. NY) 
zygotes as previously described [38]. Eight founder ammals were iden- 
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Fig. 1. KIIP-giAPP transgene. The rat insulin-I gene promoter (RIP) and exons (l-3) and introns (A,B) of the huIAPP gene are indicated; 1.1 
kb of 3’ flanking sequence is included in the construct ~thin-lined region). 5’ and 3’ untranslated regions are hatched. BssHII sites in the vector 
(jagged lines) were used for excision of the transgene msert for microinjectron. 
tified by Southern blotting, five of which yielded transgenic progeny. 
Three of these lines, #6, # 13 and # 16 tested positive for expression 
of the transgene and were used for the present studies. 
2.2. Northern blot unulmis 
Total RNA was extracted from freshly isolated tissues accordmg to 
the method of Chomczynski and Saccht [29]. For Northern analysis. 
the RNA was electrophoresed on an 18% formaldehyde/l .5% agarose 
gel, blotted onto nitrocellulose and hybridized to a 329 bp IAPP 
cDNA probe labelled with “P by PCR f30]. The mouse msuhn gene 
probe used consisted of a 60 bp, 3’P-labe11ed synthetic ohgonucleotide. 
2.3. Western blot unalysu 
Fresh tissues or isolated islets [31] were homogenized in 0.1 M NaCI, 
1 mM EDTA, 0.01 M Tris-HCl (pH 7.6) plus protease inhibitors. 
After assaying for protein concentration (BioRad Lab.. Cambridge, 
MA), the extracts were boiled, fractionated on a 4-20% Tris-glycine 
gradient gel (Novex. San Diego. CA) and electrophoretlca1ly trans- 
ferred to 0.2 ,ffrn PVDF (Bio-Rad) or nitrocellulose (S&S) membrane. 
After incubatmg with primary antiserum for one hour, reactive pro- 
tein bands were demonstrated using the enhanced chemiluminescence 
method (Amersham, Arlington Hts., IL). The primary antiserum was 
either rabbit anti-rat amylm/IAPP (Peninsula Labs. Belmont, CA) 
diluted l:lO,OOO which detects both mouse (mu) and human (hu) IAPP 
(referred to here as anti-mu/hulAPP antiserum), or rabbit anti- human 
amylin/lAPP (Peninsula Labs) diluted 12,000 and pre-absorbed with 
synthetic rat (identical to mouse) IAPP (Peninsula Labs) to render the 
antiserum huIAPP-specific. Pre-absorbed antibody was prepared by 
mcubating 0.4 ml of dtluted (1:500) antiserum with 200 ng of peptide 
for 1.5 h at room temperature just prior to use. Thts latter antiserum 
is referred to here as ant]-huIAPP. 
2.4. Histochemistry and indirect inu?~unoffiovescence ( Irf) 
Sixpm-thick frozen sections were fixed m PBS-buffered 2% parafor- 
maldehyde for 30 min and processed for IIF as previously described 
[28]. The primary antiserum was either anti-mu/huIAPP (described 
above) or anti-huIAPP (described above). Secondary antibody was 
FITC goat antI-rabbit IgG (~appe~organon Tekmka Corp., Dur- 
ham. NC). Histochemical detection of amyloid was carried out on 
tissue sections using alkaline Congo red staining and subsequent ex- 
amination under a polartzmg microscope. 
2.5. Plu.sma IAPP, insulin and glucose unalysrs 
For plasma IAPP and insulin level determinations, 12-15 etght- 
week-old transgenic mice or non-transgenic (control) siblings, were 
fasted overnight and bled retro-orbitally into tubes containing anti- 
coagulant {Sequester-Sol. Cambridge Chem. Prod. Inc., Fort Lauder- 
dale, FL). Individual plasma fractions were isolated, pooled and aliq- 
uoted (1 ml for IAPP and 0.05 ml for insulin assay). The IAPP assay 
is described m detail elsewhere [32]. Briefly, the assay IS based on 
rabbtt anti-human IAPP antiserum (Peninsula. Meerseyside. UK) 
wtth labelled rat/mouse IAPP (Amersham) as tracer and detects 
changes between adjacent samples equivalent to 1 pmol/l plasma. 
Before assay, each plasma sample was extracted on a Sep-Pak Clx 
cartridge and the eluate was lyophihzed and reconstituted in assay 
buffer. Insulin levels were dete~ined using an RIA ktt from Diagnos- 
tic Products Corporation (San Diego, CA) and rat insulin (Eli Lilly) 
as the standard. IAPP and Insulin assays were run on 3-h aliquots of 
plasma from each animal group. Blood glucose levels were determined 
on individual fasted mice (12-X mice/group) by the glucose oxtdase 
method using a model 300 Alpkem Rapid Flow Analyzer. 
3. RESULTS 
The hybrid transgene construct used for the generation 
of transgenic mice is shown in Fig. 1. Three stable lines 
of transgenic mice were created which expressed high 
Ievels of transgene mRNA in the pancreas by Northern 
analysis (Fig. 2). Transgene-derived mRNA transcripts 
observed included a major 1.6 kb transcript and several 
285- 
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Fig. 2. Northern blot analysis. Forty pm of total RNA (15 pg in 
pituitary lanes) extracted from tissues of line (L) 6, 13 and 16 progeny 
and non-t~ans~enic FVB mace was subjected to Northern blot analysis. 
Multiple transgene mRNA transcripts are detected in the pancreas in 
all three lines and in brain and pituitary of line 6. While not shown, 
line 13 and 16 mice also expressed the transgene in the brain and 
pituitary. Expression of endogenous mouse IAPP is below the level of 
detection in total pancreatic RNA using this probe. Inset: pancreatic 
RNA from lute 13 and 6 transgemc mace (left 2 lanes) and a non- 
transgemc mouse (right lane) hybrtdtzed to a mouse insulm probe. 
41 
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Ftg. 3. Indirect immunofluorescen~. (A) HuIAPP-specific antiserum reacts strongly with line 6 pancreatic islets but not with non-transgenic islets 
(B). Transgenic IAPP is also detected in a subpopulation of cells in the anterior ptuitary (a) of line 6 mice reacted with anti-mukuIAPP but not 
the intermediate (i) or posterior (p) pituitary (C), nor is endogenous muIAPP detected in the pituitary of non-transgenic mice (D). All figures x 200. 
less abundant transcripts which likely arise from multi- 
ple polyadenylation signals in the IAPP gene [33]. 
Transgene mRNA expression in the pancreas was high- 
est in line 6 by this method of detection and judged to 
be roughly equivalent o the level of endogenous insulin 
gene expression (compare the major I .6 kb transcript to 
insulin transcript in Fig. 2, inset) and at least ten-fold 
higher than that of endogenous mouse IAPP 1341. Sig- 
nificant extrapancreatic expression was also detected in 
the brain and pituitary gland in all three lines (illus- 
trated for line 6 in Fig. 2); low levels of transgene x- 
pression were detected in the intestine and testes of some 
line 13 and 16 mice but not line 6 animals (not shown). 
While expression of transgenic mRNA was detected 
in several tissues, expression of transgenic IAPP protein 
42 
was only detected in the pancreatic islets of Langerhans 
and a subpopulation of cells in the anterior pituitary 
when localized by IIF (Fig. 3). The cellular localization 
of IAPP in these tissues appeared identical in all three 
lines. Since the pattern of reactivity in the transgenic 
islets was identical with either the huIAPP-specific an- 
tiserum and antiserum specific for rat/mouse IAPP (Fig 
3; and N. Fox, unpublished findings), it is conciuded 
that both endogenous mouse and exogenous human 
IAPP are being co-synthesized in the transgenic islet 
beta cells. The specific cell type(s) expressing the trans- 
gene in the anterior pituitary were not determined: im- 
munorea~tivity in the pituitary was not due to en- 
dogenous mouse IAPP (Fig. 3D). Finally, whereas in- 
tracellular immunoreactivity for IAPP was clearly pres- 
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Fig. 4. Western blot analysis. (A) Thirty pm of protein/lane from 
pancreas (Pan), pituitary (Pit), and liver (Liv) of transgemc line (L) 6, 
13 and 16 mice and non-transgenic control mice (C) were blotted and 
reacted with anti-mu/huIAPP antiserum to examine total IAPP levels. 
IAPP is readily detected as a 3.9 kDa protein species m lanes contain- 
ing transgenic pancreas and pitmtary, non-transgenic pancreas and 
synthetic IAPP (10 ng) but not transgenic liver or non-transgenic 
pituitary. (B) Same blot as m (A) reacted with anti-mu/huIAPP anti- 
serum pre-absorbed with synthetic IAPP Reactivity with the 3.9 kDa 
IAPP band is completely abolished. (C) Blot of 10 mg of islet protein 
(= 10 islets) and 10 ng of human (Hu) and rat (R) IAPP standards 
reacted with anti-mu/huIAPP antiserum A small elevation in total 
IAPP is detected in transgenic islets. (D) Transgenic and non-trans- 
genie islets reacted with the huIAPP-specific antiserum: the 3.9 kDa 
protein is only detected m the transgemc islet extracts. 
ent in transgenic islets, no extracellular deposits of 
IAPP were detected either immunohistochemically or 
by histochemical staining of tissue sections with amy- 
loid-specific Congo red (see section 2) in transgenic mice 
as old as one year of age. 
A MW 3.9 kDa band corresponding to the processed 
form of IAPP was readily detected in protein extracts 
from transgenic or non-transgenic pancreata and trans- 
genie pituitaries by Western blot analysis (Fig. 4). No 
significant difference in the levels of total pancreatic 
IAPP was apparent between transgenic lines or between 
transgenic and non-transgenics in total pancreatic ex- 
tracts. To evaluate the IAPP levels more accurately, 
Table 1 
Plasma IAPP/insulin/glucose* 
Transgenic males 
Control + males 
IAPP 
(pmol/l) 
38.5 + 2.4 
16.7 + 2.5 
Insulin 
(pmol/l) 
200 * 38 
233 + 28 
Glucose 
(mg/dl) 
80 * 4.2 
81.4? 4.2 
Transgenic females 63.0 f 2.4 183 2 18 79.9 f 2.3 
Control females 11.3 + 1.9 200 f 27 77.6 ? 3.1 
* Assays performed on age-matched fasted animals; data expressed as 
mean + S.E.M. 
+ Controls: non-transgenic siblings. 
protein extracts from equal numbers of purified islets 
from line 6 and non-transgenic mice were compared. 
Here, total IAPP levels in transgenic islets appeared 
modestly elevated relative to non-transgenic islets (Fig. 
4C). Consistent with the IIF results, the huIAPP-spe- 
cific antiserum reacted with the MW 3.9 kDa protein in 
transgenic islet extracts but not in non-transgenic islet 
extracts (Fig. 4D), further establishing that fully proc- 
essed huIAPP is being synthesized in the transgenic is- 
lets. 
Plasma IAPP, glucose and insulin levels were criti- 
cally evaluated in fasted animals from line 6 mice which 
expressed the highest levels of transgene mRNA. These 
results are summarized in Table I. Whereas IAPP levels 
were elevated approximately 2-fold in transgenic males 
and 5-fold in transgenic females from this line, glucose 
and insulin levels remained unchanged when compared 
with sex- and age-matched non-transgenic siblings. Sim- 
ilar results have also been obtained in a smaller sam- 
pling of line 13 and 16 mice (N. Fox and G. Wester- 
mark, unpublished results). Why the plasma IAPP lev- 
els differ in transgenic male vs. female line 6 mice is 
uncertain and is under investigation. This may be due, 
for example, to a chromosomal position effect [35] 
whereby a particular transgene integration site may 
allow stronger transgene transcription in a given tissue 
in females relative to males. 
4. DISCUSSION 
The expression of the RIlP-gIAPP transgene in the 
pancreas and the brain in our transgenic animals is 
consistent with an earlier report that sequences from 
-346 to -103 bp flanking the insulin-I gene promoter 
will direct transgene expression to these sites [36]. Ex- 
pression of the transgene in the anterior pituitary in all 
three lines was unexpected and may have resulted from 
the unmasking of cryptic regulatory elements in the 
human IAPP gene and/or a novel interaction between 
the rat insulin I gene promoter/flank and the IAPP gene. 
RIlP-gIAPP mRNA transcripts were also detected in 
the brain, yet no immunoreactive IAPP was detected 
here. Notably, the RIlP-gIAPP mRNA transcripts in 
brain were found to correspond to sense-strand (hence 
potentially translatable) huIAPP mRNAs by hybridiza- 
tion to sense and anti-sense riboprobes (G. Wester- 
mark, unpublished results). Thus, this suggests that 
translational or post-translational synthesis/processing 
of IAPP may be inefficient in this tissue. 
There did not appear to be a major elevation of total 
IAPP protein in the islets despite a high level of trans- 
gene mRNA expression and IAPP in the blood. This 
could be due to a higher rate of IAPP release from the 
transgenic islets. Translational or post-translational 
regulatory mechanisms may also affect IAPP produc- 
tion as suggested in earlier experiments by our group 
1371. 
43 
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The fold-increase in blood IAPP levels in female 
transgenic line 6 mice relative to control animals was 
significantly greater than the highest reported physiol- 
ogic increase observed in man (i.e. 2-3-fold) following 
glucose challenge (reviewed in [I 11). Despite this eleva- 
tion, no change in blood glucose levels was evident as 
might have been expected if IAPP had a significant 
glucoregulatory function as proposed [20]. Failure to 
reveal such an effect was not due to a compensatory 
increase in insulin secretion as insulin levels were nor- 
mal in the transgenics. Hence, under the present condi- 
tions, IAPP does not appear to exhibit significant glu- 
coregulatory activity. 
We have not detected the presence of amyloid depos- 
its in the islets (or pituitary) by Congo red staining of 
histologic sections from mice as old as one year of age. 
Amyloid formation may require more time and/or a 
predisposing event such as concurrent diabetes. Since 
these conditions can be experimentally invoked and/or 
genetically introduced into mice by interbreeding with 
diabetes-prone dbldb and oblob mice, these transgenics 
should provide a unique model for further exploration 
of the factors involved in islet amyloidogenesis and 
NIDDM. 
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